Alzinova

Alzinova Gross Margin

The Gross Margin of Alzinova (ALZ.ST) as of Nov 18, 2026 is 56,036.67 %. In the previous year, Gross Margin was 7,360.74 % — a change of 661.29% (higher).

Gross Margin

56,036.67 %

YoY

661.29%

Last updated:

Gross Margin of Alzinova is 2024 56,036.67 % . Gross Margin of Alzinova was 2023 7,360.74 % . It decreases by 661.29% higher compared to the previous year.

For Alzinova, the gross margin of 56,036.7% is up versus 100.0% a few years ago.

The Alzinova Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2017
188.83 SEK
Jan 1, 2018
199.86 SEK
Jan 1, 2019
100.00 SEK
Jan 1, 2020
100.00 SEK
Jan 1, 2021
100.00 SEK
Jan 1, 2022
200.00 SEK
Jan 1, 2023
7,360.74 SEK
Jan 1, 2024
56,036.67 SEK
The Alzinova Gross Margin history
YEARGross MarginYoY
56,036.67 %+661.29%
7,360.74 %+3,580.37%
200.00 %+100.00%
100.00 %0.00%
100.00 %0.00%
100.00 %-49.97%
199.86 %+5.84%
188.83 %-2.21%
193.09 %+93.09%
100.00 %+307.43%
24.54 %+11,518.99%
0.21 %+139.61%
0.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alzinova Stock analysis

What does Alzinova do? Alzinova AB develops therapeutics for Alzheimer's disease, focusing on ALZ-101, an oligomer-directed vaccine, and ALZ-201, a diagnostic based on a monoclonal antibody. The company targets the oligomeric Aβ form that damages brain synapses, aiming to provide treatments and diagnostics for Alzheimer's patients. ALZ-101 and ALZ-201 are the primary products driving revenue through research and development partnerships with pharmaceutical companies. The company's products ALZ-101 and ALZ-201 are developed for the Alzheimer's disease treatment segment. ALZ-101 is a vaccine targeting oligomeric Aβ, while ALZ-201 serves as a diagnostic tool. These products are sold to pharmaceutical companies for further development and commercialization, generating revenue through licensing agreements and research collaborations. Alzinova AB's revenue model relies on the development of ALZ-101 and ALZ-201, with pharmaceutical companies purchasing rights to these therapeutics and diagnostics. The firm's focus on oligomeric Aβ-specific treatments positions it within the Alzheimer's disease therapeutics market, where it partners with larger pharmaceutical firms for product advancement and market entry. Alzinova is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alzinova stock

Gross Margin of Alzinova is 56,036.67 % in 2024.

Gross Margin of Alzinova changed from 7,360.74 % to 56,036.67 %, representing a 661.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Alzinova since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Alzinova with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Alzinova

All Key Metrics — Alzinova